Crohn's Disease Clinical Trials in Indianapolis, Indiana

9 studies are recruiting for crohn's disease in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Indiana University Health University Hospital ( Site 5022), Indianapolis, Indiana

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

2. A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

   Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active C…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis, Indiana

   Locations

   85 in total

   Run by

   AbbVie

   See if you can join NCT05995353 on ClinicalTrials.gov

3. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

   The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Indiana University Health University Hospital, Indianapolis, Indiana

   Locations

   183 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06937099 on ClinicalTrials.gov

4. A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Riley Hospital for Children, Indianapolis, Indiana

   Locations

   85 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05923073 on ClinicalTrials.gov

5. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

   Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Riley Childrens Hospital, Indianapolis, Indiana

   Locations

   81 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05509777 on ClinicalTrials.gov

6. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

   Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Indiana University Health University Hospital /ID# 278129, Indianapolis, Indiana

   Locations

   255 in total

   Run by

   AbbVie

   See if you can join NCT06548542 on ClinicalTrials.gov

7. Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

   Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effec…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis, Indiana

   Locations

   85 in total

   Run by

   AbbVie

   See if you can join NCT06332534 on ClinicalTrials.gov

8. A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

   The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Diseas…

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Indiana University (IU) Health University Hospital, Indianapolis, Indiana

   Locations

   138 in total

   Run by

   Takeda

   See if you can join NCT06227910 on ClinicalTrials.gov

9. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

   The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Riley Hospital For Children - PIN, Indianapolis, Indiana

   Locations

   98 in total

   Run by

   Takeda

   See if you can join NCT05442567 on ClinicalTrials.gov